BIOMEDICA CRO’s Post

We at BIOMEDICA CRO are fully equipped to support studies that require #BoneMarrow and other #Biospecimens from patients with hematologic malignancies 🎗 📩 Contact us at office@biomedica-cro.com to receive a customized quote tailored to your project needs. #PrecisionMedicine #Research #CRO #Biotech #TranslationResearch #Oncology #CancerResearch

Key factor determining aggressive variant of pulmonary carcinoids discovered The clinical course of pulmonary carcinoids ranges from curable tumors to lethal variants, suggesting that specific molecular alterations drive progression toward the fully malignant state. The biological determinants of the diverse clinical phenotypes, however, have remained unclear to date. In a collaborative study, published in the Journal of Clinical Oncology, researchers from the Department of Experimental Pediatric Oncology, in the University Children’s Hospital, and the Department of Translational Genomics, both at the University of Cologne, have discovered that induction of the gene TERT, encoding for telomerase reverse transcriptase, is a defining feature of the aggressive variant of pulmonary carcinoids. Telomerase is an enzyme that is essential for stabilizing the ends of the chromosomes, the telomeres. Normal cells, lack telomerase, which limits their capacity to replicate. By contrast, cancerous cells frequently regain telomerase activity, which thus confers replicative immortality. The scientists  found that pulmonary carcinoids with poor clinical outcome are characterized by induction of TERTexpression and telomerase activity, while telomerase activity was absent in carcinoids with favorable outcome. These findings are in line with previous observations in pediatric neuroblastoma, in which a deadly course of disease is also driven by the presence of telomere maintenance mechanisms. The results of the current study will allow to more accurately predict the course of disease in patients with pulmonary carcinoids, which will enable tailoring of treatment intensities according to the individual patient risk. More broadly, the results highlight activation of telomere maintenance as a key feature of lethal cancers, making telomerase an attractive therapeutic target for development of novel cancer medicines. Werr L, Bartenhagen C, Rosswog C, Cartolano M, Voegele C, Sexton-Oates A, Di Genova A, Ernst A, Kahlert Y, Hemstedt N, Höppner S, Mansuet Lupo A, Pelosi G, Brcic L, Papotti M, George J, Bosco G, Quaas A, Tang LH, Robzyk K, Kadota K, Roh MS, Fanaroff RE, Falcon CJ, Büttner R, Lantuejoul S, Rekhtman N, Rudin CM, Travis WD, Alcala N, Fernandez-Cuesta L, Foll M, Peifer M, Thomas RK, Fischer M. TERT expression and clinical outcome in pulmonary carcinoids. J Clin Oncol 2024

Key factor determining aggressive variant of pulmonary carcinoids discovered The clinical course of pulmonary carcinoids ranges from curable tumors to lethal variants, suggesting that specific molecular alterations drive progression toward the fully malignant state. The biological determinants of the diverse clinical phenotypes, however, have remained unclear to date. In a collaborative study, published in the Journal of Clinical Oncology, researchers from the Department of Experimental Pediatric Oncology, in the University Children’s Hospital, and the Department of Translational Genomics, both at the University of Cologne, have discovered that induction of the gene TERT, encoding for telomerase reverse transcriptase, is a defining feature of the aggressive variant of pulmonary carcinoids. Telomerase is an enzyme that is essential for stabilizing the ends of the chromosomes, the telomeres. Normal cells, lack telomerase, which limits their capacity to replicate. By contrast, cancerous cells frequently regain telomerase activity, which thus confers replicative immortality. The scientists  found that pulmonary carcinoids with poor clinical outcome are characterized by induction of TERTexpression and telomerase activity, while telomerase activity was absent in carcinoids with favorable outcome. These findings are in line with previous observations in pediatric neuroblastoma, in which a deadly course of disease is also driven by the presence of telomere maintenance mechanisms. The results of the current study will allow to more accurately predict the course of disease in patients with pulmonary carcinoids, which will enable tailoring of treatment intensities according to the individual patient risk. More broadly, the results highlight activation of telomere maintenance as a key feature of lethal cancers, making telomerase an attractive therapeutic target for development of novel cancer medicines. Werr L, Bartenhagen C, Rosswog C, Cartolano M, Voegele C, Sexton-Oates A, Di Genova A, Ernst A, Kahlert Y, Hemstedt N, Höppner S, Mansuet Lupo A, Pelosi G, Brcic L, Papotti M, George J, Bosco G, Quaas A, Tang LH, Robzyk K, Kadota K, Roh MS, Fanaroff RE, Falcon CJ, Büttner R, Lantuejoul S, Rekhtman N, Rudin CM, Travis WD, Alcala N, Fernandez-Cuesta L, Foll M, Peifer M, Thomas RK, Fischer M.  TERT expression and clinical outcome in pulmonary carcinoids. J Clin Oncol 2024

Can circulating tumor DNA serial measurement using NGS predict responders and non responders to Pembrolizumab therapy in naive Non Small Cell Lung cancer patients-exciting results from BR .36 multicentric study A small 50 patients multicentric study, which measured circulating tumor DNA on a serial basis has thrown up interesting results. This phase 2 study was led by Anagnostou and it has been published in Nature Medicine (Anagnostou A, et al. Nat Med. 2023;doi:10.1038/s41591-023-02598-9) .The study evaluated finally 35 patients (70% of study population) ( 2 due to Non evaluable due to acute deterioration or death, 10 due to undetectable circulating tumor DNA and 3 due to missed plasma). The study found that after cycle 3 with Pembrolizumab, Circulating Tumor DNA levels dropped significantly and the it matched with imaging results as well with high sensitivity & specificity ( 82% & 75%). While this study has lot of limitations, it provides direction to identify responders and potential non responders and change in treatment strategy for non responders. If this study can be replicated in a large patient population, it can make precision medicine much sharper and can provide significant pharmacoeconomic benefit.

Understanding Leukemia 🩸 Leukemia, a complex blood cancer, affects millions worldwide, yet misconceptions persist. Let's delve deeper into this condition: 1️⃣ Types: Leukemia manifests in various forms, including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML). Each requires tailored treatment. 2️⃣ Causes: While specific triggers remain elusive, factors such as genetic predisposition, exposure to radiation or certain chemicals, and immune system abnormalities may play a role. 3️⃣ Symptoms: Early detection is vital. Look out for persistent fatigue, frequent infections, easy bruising or bleeding, swollen lymph nodes, and unexplained weight loss. 4️⃣ Diagnosis: Physicians rely on blood tests, bone marrow biopsy, and imaging studies for accurate diagnosis. Timely detection increases treatment success rates. 5️⃣ Treatment: Options range from chemotherapy and radiation therapy to targeted drug therapy and stem cell transplant, depending on the type and stage of leukemia. 6️⃣ Support: Patients and their loved ones require comprehensive support. From emotional encouragement to access to resources and support groups, a strong support system is invaluable. 7️⃣ Advancements: Ongoing research fuels hope. Innovations in precision medicine, immunotherapy, and genetic testing promise improved outcomes and quality of life for leukemia patients. Let's unite to raise awareness, dispel myths, and support those impacted by leukemia. Together, we can foster understanding and drive progress in combating this challenging disease. #leukemiaawareness #medicalscience #supportpatients https://lnkd.in/grZYEU8a

https://lnkd.in/eAY-e5gw Article title: Using recombinant human G-CSF to treat chemotherapy-induced neutropenia over 3 decades: What is next? Author(s): Jason Xu; Jonathan Sussman; Jessica Xu; Xing Zhao; Xiao Qiang Yan Journal: Annals of Bone Marrow Research   Journal ISSN: 2692-4684 Abstract: Chemotherapy-Induced Neutropenia (CIN) is a potentially fatal side effect of cancer treatment, affecting > 50% of cancer patients treated with chemotherapy. Clinical use of recombinant human granulocyte colony-stimulating factor (rhG-CSF) has allowed for primary and secondary prophylaxis of CIN and its sequela (i.e., febrile neutropenia, fatal infection) during myelosuppressive chemotherapy. Here, we review the translation and properties of first, second, and third-generation rhG-CSF molecules, including filgrastim (Neupogen, FDA approved in 1991) and biosimilars, pegfilgrastim (Neulasta, FDA approved in 2002) and biosimilars, and F-627 (Ryzneuta, NMPA approved in 2023), a novel long-acting rhG-CSF agent developed this past decade. Even with the development of increasingly personalized and targeted cancer therapy, chemotherapy, and stem cell transplantation remains a backbone for the majority of patients with advanced cancers, especially in the hematopoietic system. As such, more than 20 million cancer patients have been treated with rhG-CSF drugs since the first approval of filgrastim. In the next decade, we envision third-generation rhG-CSF products such as Ryzneuta lowering costs to patients and healthcare providers, expanding access to this essential medication for cancer patients worldwide, particularly for patients who require more aggressive chemotherapy treatment. #rhGCSF #Colonystimulatingfactors #Neupogen #Neulasta #Ryzneuta #Neutropenia #Chemotherapy #BoneMarrow #BloodSamples #Hematology #AutoimmuneDiseases #StemCells #Immunology #Transplantation #MinimalInvasiveSurgeryTechniques #TranscriptionFactors #Medication #TropicalTreatments #Metabolism #Mortality #DrugTargeting #DrugSensitivity #Resistance #HabitsAndLifestyle #PrognosticFactors #Pathophysiology #NovelDrugs #CellularTherapy #TranslationalResearch #MesenchymalStemCell #HematopoieticStemCellTransplantation #BoneMarrowTransplantation #BoneMarrowEdema #BoneMarrowCancer #BoneMarrowBarrier  

Hematological Malignancies Market Growth Trends Analysis and Dynamic Demand, Forecast 2024 to 2033 https://lnkd.in/d97JA5Uq Hematological malignancies refer to cancers that originate in the blood-forming tissues, such as bone marrow, or in the cells of the immune system. These include various types of leukemia, lymphoma, and multiple myeloma. The treatment landscape for hematological malignancies has evolved significantly, with advancements in targeted therapies, immunotherapies, and personalized medicine playing a central role in improving patient outcomes. Market Size and Growth The hematological malignancies market is experiencing robust growth, driven by the increasing incidence of blood cancers, advancements in diagnostic technologies, and the development of novel treatment options. The market's expansion is further supported by rising healthcare expenditures, particularly in developed regions, and increased awareness about hematological cancers. The introduction of innovative therapies, such as CAR-T cell therapy and monoclonal antibodies, has also significantly contributed to the market's growth. Key Components of the Hematological Malignancies Market Disease Types: Leukemia: Includes various subtypes such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML). Lymphoma: Includes Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL), with several subtypes such as diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. Multiple Myeloma: A cancer of plasma cells, leading to bone damage, kidney failure, and immune system dysfunction. Treatment Modalities: Chemotherapy: Traditional chemotherapy remains a cornerstone in the treatment of many hematological malignancies, despite the emergence of newer therapies. Targeted Therapy: Includes tyrosine kinase inhibitors (TKIs), B-cell receptor inhibitors, and other small molecules that specifically target cancer cells. Immunotherapy: Encompasses monoclonal antibodies, CAR-T cell therapy, and immune checkpoint inhibitors, which harness the body's immune system to fight cancer. Stem Cell Transplantation: Hematopoietic stem cell transplantation (HSCT) is used for patients with certain high-risk or relapsed hematological cancers. Radiation Therapy: Used in specific cases, particularly in combination with other treatments. End-User Segments: Hospitals: Primary centers for the administration of complex treatments such as chemotherapy, immunotherapy, and stem cell transplantation. Cancer Treatment Centers: Specialized centers focusing on comprehensive care for cancer patients, including advanced therapeutic options. Academic and Research Institutes: Conduct clinical trials and research to develop new therapies and improve existing treatment protocols. Pharmacies: Distribute oral targeted therapie

Hematological Malignancies Market Growth Trends Analysis and Dynamic Demand, Forecast 2024 to 2033 https://lnkd.in/d97JA5Uq Hematological malignancies refer to cancers that originate in the blood-forming tissues, such as bone marrow, or in the cells of the immune system. These include various types of leukemia, lymphoma, and multiple myeloma. The treatment landscape for hematological malignancies has evolved significantly, with advancements in targeted therapies, immunotherapies, and personalized medicine playing a central role in improving patient outcomes. Market Size and Growth The hematological malignancies market is experiencing robust growth, driven by the increasing incidence of blood cancers, advancements in diagnostic technologies, and the development of novel treatment options. The market's expansion is further supported by rising healthcare expenditures, particularly in developed regions, and increased awareness about hematological cancers. The introduction of innovative therapies, such as CAR-T cell therapy and monoclonal antibodies, has also significantly contributed to the market's growth. Key Components of the Hematological Malignancies Market Disease Types: Leukemia: Includes various subtypes such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML). Lymphoma: Includes Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL), with several subtypes such as diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. Multiple Myeloma: A cancer of plasma cells, leading to bone damage, kidney failure, and immune system dysfunction. Treatment Modalities: Chemotherapy: Traditional chemotherapy remains a cornerstone in the treatment of many hematological malignancies, despite the emergence of newer therapies. Targeted Therapy: Includes tyrosine kinase inhibitors (TKIs), B-cell receptor inhibitors, and other small molecules that specifically target cancer cells. Immunotherapy: Encompasses monoclonal antibodies, CAR-T cell therapy, and immune checkpoint inhibitors, which harness the body's immune system to fight cancer. Stem Cell Transplantation: Hematopoietic stem cell transplantation (HSCT) is used for patients with certain high-risk or relapsed hematological cancers. Radiation Therapy: Used in specific cases, particularly in combination with other treatments. End-User Segments: Hospitals: Primary centers for the administration of complex treatments such as chemotherapy, immunotherapy, and stem cell transplantation. Cancer Treatment Centers: Specialized centers focusing on comprehensive care for cancer patients, including advanced therapeutic options. Academic and Research Institutes: Conduct clinical trials and research to develop new therapies and improve existing treatment protocols. Pharmacies: Distribute oral targeted therapie

📃Scientific paper: Thyroid autoimmunity and hypothyroidism are associated with deep molecular response in patients with chronic myeloid leukemia on tyrosine kinase inhibitors Abstract: Purpose Thyroid alterations including de novo appearance of thyroid autoimmunity are adverse effects of tyrosine kinase inhibitors, used in solid and hematologic cancer therapy, but the relationship between thyroid alterations during this treatment and the outcome of chronic myeloid leukemia remains unclear. Aim of this study was to investigate whether the presence of thyroid alterations may affect the clinical outcome of chronic myeloid leukemia on tyrosine kinase inhibitors. Methods We evaluated thyroid function and autoimmunity in 69 chronic myeloid leukemia patients on long-term therapy looking at the association between thyroid abnormalities and disease molecular response. Results Overall, 24 of 69 (34.8%) had one or more thyroid abnormalities during therapy. A high percentage of patients (21/69, 30.4%) showed thyroid autoimmunity (positive thyroid autoantibodies with ultrasound hypoechogenicity), while clinical and subclinical hypothyroidism and subclinical hyperthyroidism were, respectively, found in 4 of 69 (5.8%) and 3 of 69 (4.3%) of cases. Second-generation tyrosine kinase inhibitors resulted significantly associated (14/32, 43.7%) with Hashimoto’s thyroiditis, compared to first generation (7/37, 18.9%; p  = 0.03). Interestingly, we also found a significant association between euthyroid (14/26, 53.8%) and hypothyroid Hashimoto’s thyroiditis (4/26, 15.4%) in patients with deep molecular response, as compared to euthyroid (3/43, 7%; p  = 0.0001) and hypothyro... Discover the rest of the scientific article on es/iode ➡️https://etcse.fr/FcL8u

**Groundbreaking Results for Chinese CAR-T Therapy: 86% Response Rate of BCMA/GPRC5D Dual-Target Treatment** #MultipleMyeloma #ChineseCART #BCMA #GPRC5D #DualTarget #MM #RRMM Multiple myeloma (MM) is a challenging blood cancer, particularly in relapsed/refractory (R/R) cases. While therapies like proteasome inhibitors, immunomodulators, CD38 monoclonal antibodies, and stem cell transplants have improved outcomes for newly diagnosed patients, treatment-resistant forms of MM remain a serious concern. A new therapeutic approach combining two targets, BCMA and GPRC5D, may provide a breakthrough solution. BCMA has long been a key target for treating R/R MM due to its expression in malignant plasma cells. However, BCMA-targeted therapies face limitations, including tumor cells losing or downregulating BCMA, leading to disease recurrence. This is where GPRC5D, a protein highly expressed in MM cells and linked to poor prognosis, comes in. By targeting both BCMA and GPRC5D, researchers aim to overcome the limitations of single-target therapies. A collaboration between a leading Chinese hospital and research institutions has now delivered promising results. A Phase I clinical trial involving 21 patients with R/R MM using the dual-target BCMA/GPRC5D CAR-T cell therapy reported an overall response rate (ORR) of 86%, with 75% of patients achieving a complete response (CR). Notably, even patients whose cancer cells lacked BCMA or GPRC5D expression showed significant improvement, underscoring the versatility of this treatment. **Key Results from the Study:** - 21 patients with advanced, heavily pre-treated R/R MM participated. - Of the 12 patients who received the optimal dosage of 2.0×10⁶ CAR-T cells/kg, 86% showed clinical response, with 75% achieving complete remission. - Importantly, patients with BCMA or GPRC5D-negative cancer cells also responded well to treatment. - The treatment was well-tolerated, with manageable side effects, including 71% of patients experiencing mild to moderate cytokine release syndrome (CRS). This trial, published in *The Lancet Haematology*, represents a major step forward in MM treatment. The dual-target approach addresses the limitations of BCMA-targeted therapies, offering new hope to patients who have exhausted conventional options. Looking ahead, this innovative therapy could reshape the future of multiple myeloma treatment, offering a powerful new tool in the fight against this complex disease. To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine In China for preliminary evaluation! WhatsApp: +8613717959070 Email: doctor.huang@globecancer.com #CancerResearch #MultipleMyeloma #CAR_TTherapy #MedicalInnovation #OncologyBreakthrough